FAKTOR-OPTIONSSCHEIN - GENMAB | Real-time Bid/Ask 08:47:51 2024-06-26 EDT | ||
| 2.87 EUR / 2.89 EUR | +1.41% |
|
| 1 month | -21.29% | ||
| 3 months | -38.91% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GENMAB A/S
| Date | Price | Change |
|---|---|---|
| 24-06-26 | 2.92 | +2.82% |
| 24-06-25 | 2.92 | +2.82% |
| 24-06-24 | 2.84 | -4.05% |
| 24-06-21 | 2.96 | +2.42% |
| 24-06-20 | 2.89 | +4.71% |
Delayed Quote Börse Stuttgart
Last update June 26, 2024 at 07:52 am
More quotesStatic data
| Product type | Produits Exotiques |
|---|---|
| Buy / Sell | CALL |
| Underlying | GENMAB A/S |
| Issuer | Morgan Stanley |
| WKN | MD4YW1 |
| ISIN | DE000MD4YW12 |
| Date issued | 2022-06-06 |
| Strike | 1,204 kr |
| Maturity | Unlimited |
| Parity | 27.46 : 1 |
| Emission price | 10 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 34.02 € |
|---|---|
| Lowest since issue | 2.7 € |
| Spread | 0.02 € |
| Spread % | 0.68% |
Company Profile
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Sector
-
Consensus: Genmab A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
1,799
DKK
Average target price
2,464
DKK
Spread / Average Target
+36.96%
- Stock Market
- Certificates
- Certificat
